These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27936766)

  • 1. Discovery of Mycobacterium tuberculosis InhA Inhibitors by Binding Sites Comparison and Ligands Prediction.
    Štular T; Lešnik S; Rožman K; Schink J; Zdouc M; Ghysels A; Liu F; Aldrich CC; Haupt VJ; Salentin S; Daminelli S; Schroeder M; Langer T; Gobec S; Janežič D; Konc J
    J Med Chem; 2016 Dec; 59(24):11069-11078. PubMed ID: 27936766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Matviiuk T; Rodriguez F; Saffon N; Mallet-Ladeira S; Gorichko M; de Jesus Lopes Ribeiro AL; Pasca MR; Lherbet C; Voitenko Z; Baltas M
    Eur J Med Chem; 2013; 70():37-48. PubMed ID: 24140915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview on crystal structures of InhA protein: Apo-form, in complex with its natural ligands and inhibitors.
    Chollet A; Maveyraud L; Lherbet C; Bernardes-Génisson V
    Eur J Med Chem; 2018 Feb; 146():318-343. PubMed ID: 29407960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiolabelling and positron emission tomography of PT70, a time-dependent inhibitor of InhA, the Mycobacterium tuberculosis enoyl-ACP reductase.
    Wang H; Liu L; Lu Y; Pan P; Hooker JM; Fowler JS; Tonge PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4782-4786. PubMed ID: 26227776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach.
    Pauli I; dos Santos RN; Rostirolla DC; Martinelli LK; Ducati RG; Timmers LF; Basso LA; Santos DS; Guido RV; Andricopulo AD; Norberto de Souza O
    J Chem Inf Model; 2013 Sep; 53(9):2390-401. PubMed ID: 23889525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing mechanisms of resistance to the tuberculosis drug isoniazid: Conformational changes caused by inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis.
    Kruh NA; Rawat R; Ruzsicska BP; Tonge PJ
    Protein Sci; 2007 Aug; 16(8):1617-27. PubMed ID: 17600151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.
    Kanetaka H; Koseki Y; Taira J; Umei T; Komatsu H; Sakamoto H; Gulten G; Sacchettini JC; Kitamura M; Aoki S
    Eur J Med Chem; 2015 Apr; 94():378-85. PubMed ID: 25778993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis.
    Shirude PS; Madhavapeddi P; Naik M; Murugan K; Shinde V; Nandishaiah R; Bhat J; Kumar A; Hameed S; Holdgate G; Davies G; McMiken H; Hegde N; Ambady A; Venkatraman J; Panda M; Bandodkar B; Sambandamurthy VK; Read JA
    J Med Chem; 2013 Nov; 56(21):8533-42. PubMed ID: 24107081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth.
    Chollet A; Mori G; Menendez C; Rodriguez F; Fabing I; Pasca MR; Madacki J; Korduláková J; Constant P; Quémard A; Bernardes-Génisson V; Lherbet C; Baltas M
    Eur J Med Chem; 2015 Aug; 101():218-35. PubMed ID: 26142487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical synthesis and in silico molecular modeling of novel pyrrolyl benzohydrazide derivatives: Their biological evaluation against enoyl ACP reductase (InhA) and Mycobacterium tuberculosis.
    Joshi SD; More UA; Dixit SR; Balmi SV; Kulkarni BG; Ullagaddi G; Lherbet C; Aminabhavi TM
    Bioorg Chem; 2017 Dec; 75():181-200. PubMed ID: 28961440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
    Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
    Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis.
    Chollet A; Stigliani JL; Pasca MR; Mori G; Lherbet C; Constant P; Quémard A; Bernadou J; Pratviel G; Bernardes-Génisson V
    Chem Biol Drug Des; 2016 Nov; 88(5):740-755. PubMed ID: 27301022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA.
    Prati F; Zuccotto F; Fletcher D; Convery MA; Fernandez-Menendez R; Bates R; Encinas L; Zeng J; Chung CW; De Dios Anton P; Mendoza-Losana A; Mackenzie C; Green SR; Huggett M; Barros D; Wyatt PG; Ray PC
    ChemMedChem; 2018 Apr; 13(7):672-677. PubMed ID: 29399991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docking studies on novel alkaloid tryptanthrin and its analogues against enoyl-acyl carrier protein reductase (InhA) of Mycobacterium tuberculosis.
    Tripathi A; Wadia N; Bindal D; Jana T
    Indian J Biochem Biophys; 2012 Dec; 49(6):435-41. PubMed ID: 23350278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.